Published in Lancet on November 17, 2010
The Effect of Renal Denervation on Biological Variables | NCT01427049
Impact of Renal SympAthetic DenerVation on Chronic HypErtension (SAVE) | NCT01628198
Impact of Catecholamine Spill-over on Outcome After RDN and EP Ablation (RDN-Cath-1) | NCT01875809
Renal Denervation Hypertension After Stroke (REHEARSE) | NCT01689415
Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int (2011) 3.32
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Early reduction of therapy-resistant hypertension in a patient after single-sided renal denervation approach. Clin Res Cardiol (2013) 2.13
Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension (2011) 1.97
Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens (2013) 1.88
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol (2013) 1.78
Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J (2013) 1.77
Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res (2011) 1.72
Under pressure: the search for the essential mechanisms of hypertension. Nat Med (2011) 1.72
Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol (2013) 1.70
Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res (2014) 1.68
Safety and efficacy of renal denervation as a novel treatment of ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm (2013) 1.63
Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol (2011) 1.58
Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res (2014) 1.56
Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis (2014) 1.53
Cardiovascular remodelling in coronary artery disease and heart failure. Lancet (2014) 1.47
Updated national and international hypertension guidelines: a review of current recommendations. Drugs (2014) 1.41
Vascular inflammatory cells in hypertension. Front Physiol (2012) 1.37
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension (2012) 1.35
Treatment resistant hypertension--investigation and conservative management. Dtsch Arztebl Int (2014) 1.32
Neural mechanisms of angiotensin II-salt hypertension: implications for therapies targeting neural control of the splanchnic circulation. Curr Hypertens Rep (2011) 1.29
Cardiac innervation and sudden cardiac death. Circ Res (2015) 1.29
Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol (2011) 1.28
The sympathetic nervous system alterations in human hypertension. Circ Res (2015) 1.28
Sympatho-renal axis in chronic disease. Clin Res Cardiol (2011) 1.26
Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension (2011) 1.15
Effect of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. J Interv Card Electrophysiol (2012) 1.08
Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs. Am J Hypertens (2014) 1.08
The rise, fall, and possible resurrection of renal denervation. Nat Rev Cardiol (2016) 1.06
Pathogenesis of obstructive sleep apnoea in hypertensive patients: role of fluid retention and nocturnal rostral fluid shift. J Hum Hypertens (2014) 1.04
Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension (2013) 1.04
Renalase's expression and distribution in renal tissue and cells. PLoS One (2012) 1.04
Obstructive sleep apnea and insight into mechanisms of sympathetic overactivity. J Clin Invest (2014) 1.03
Proteinuria and its relation to cardiovascular disease. Int J Nephrol Renovasc Dis (2013) 1.02
Role of renal sensory nerves in physiological and pathophysiological conditions. Am J Physiol Regul Integr Comp Physiol (2014) 1.02
Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol (2013) 1.00
Impact of renal denervation on renalase expression in adult rats with spontaneous hypertension. Exp Ther Med (2012) 0.99
Pressure natriuresis and the renal control of arterial blood pressure. J Physiol (2014) 0.98
Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol (2013) 0.97
The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol (2014) 0.96
Potential reduction of interstitial myocardial fibrosis with renal denervation. J Am Heart Assoc (2014) 0.96
Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine (Baltimore) (2014) 0.96
Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol (2013) 0.95
Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J (2011) 0.95
Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol (2012) 0.95
Renal sympathetic denervation: the jury is still out. Lancet (2010) 0.95
Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol (2012) 0.95
Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am (2013) 0.95
Revelations about carotid body function through its pathological role in resistant hypertension. Curr Hypertens Rep (2013) 0.94
The role of the kidney in regulating arterial blood pressure. Nat Rev Nephrol (2012) 0.94
Long-term renal denervation normalizes disrupted blood pressure circadian rhythm and ameliorates cardiovascular injury in a rat model of metabolic syndrome. J Am Heart Assoc (2013) 0.94
Time-dependent changes in autonomic control of splanchnic vascular resistance and heart rate in ANG II-salt hypertension. Am J Physiol Heart Circ Physiol (2011) 0.94
Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens (2013) 0.93
Catheter-based renal sympathetic denervation significantly inhibits atrial fibrillation induced by electrical stimulation of the left stellate ganglion and rapid atrial pacing. PLoS One (2013) 0.93
CrossTalk opposing view: Which technique for controlling resistant hypertension? Renal nerve ablation. J Physiol (2014) 0.93
Methodological standardization for the pre-clinical evaluation of renal sympathetic denervation. JACC Cardiovasc Interv (2014) 0.92
Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. Diabetologia (2015) 0.92
Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. J Physiol (2016) 0.92
Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension (2015) 0.92
Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol (2012) 0.91
Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol (2013) 0.91
Renal denervation: a new treatment option in resistant arterial hypertension. Neth Heart J (2013) 0.91
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. Clin Hypertens (2015) 0.90
Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension. Am J Physiol Heart Circ Physiol (2013) 0.89
Translational neurocardiology: preclinical models and cardioneural integrative aspects. J Physiol (2016) 0.89
Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clin Res Cardiol (2015) 0.89
Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89
Effects of exercise training on cardiovascular adrenergic system. Front Physiol (2013) 0.88
Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol (2015) 0.88
Methods and considerations for the analysis and standardization of assessing muscle sympathetic nerve activity in humans. Auton Neurosci (2015) 0.87
Medication adherence and resistant hypertension. J Hum Hypertens (2014) 0.87
Early life stress sensitizes the renal and systemic sympathetic system in rats. Am J Physiol Renal Physiol (2013) 0.87
Autonomic dysfunction in essential hypertension: A systematic review. Ann Med Surg (Lond) (2013) 0.87
Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system. Cardiol Res Pract (2012) 0.87
Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. Clin Res Cardiol (2016) 0.86
Redo renal denervation using a multi-electrode radiofrequency system in patients with persistent therapy-resistant hypertension. Neth Heart J (2017) 0.86
Renal sympathetic denervation for treatment of resistant hypertension - indigenous technique. Indian Heart J (2013) 0.86
Effects of Renal Sympathetic Denervation on 24-hour Blood Pressure Variability. Front Physiol (2012) 0.86
Assessment and management of resistant hypertension. CMAJ (2014) 0.86
The effects of catheter-based radiofrequency renal denervation on renal function and renal artery structure in patients with resistant hypertension. J Clin Hypertens (Greenwich) (2014) 0.86
Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension. Clin Res Cardiol (2014) 0.85
Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin Res Cardiol (2010) 0.85
Oxidative stress in the brain causes hypertension via sympathoexcitation. Front Physiol (2012) 0.85
Renal sympathetic denervation using an externally irrigated radiofrequency ablation catheter for treatment of resistant hypertension - Acute safety and short term efficacy. Indian Heart J (2015) 0.85
The baroreflex as a long-term controller of arterial pressure. Physiology (Bethesda) (2015) 0.85
Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. Heart (2014) 0.85
Neuroimmune communication in hypertension and obesity: a new therapeutic angle? Pharmacol Ther (2013) 0.85
Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol (2013) 0.85
Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides. Am J Physiol Regul Integr Comp Physiol (2013) 0.85
Can physiology zap therapeutic sweet spots in hypertension? Hypertension (2012) 0.85
Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing. PLoS One (2013) 0.85
Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. J Am Soc Nephrol (2014) 0.85
Hypertension in hemodialysis patients: an opinion-based update. Semin Dial (2014) 0.85
Hypertension in 2011: New insights--from risk factors to treatment implications. Nat Rev Cardiol (2011) 0.84
Central mechanisms of abnormal sympathoexcitation in chronic heart failure. Cardiol Res Pract (2012) 0.84
Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control (2013) 0.84
Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation. J Appl Physiol (1985) (2012) 0.84
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med (2005) 12.03
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet (2009) 10.53
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med (2012) 9.22
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88
Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol (2007) 6.12
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med (2010) 4.42
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A (2005) 4.13
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 4.07
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol (2012) 3.56
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48
Renin-angiotensin system and cardiovascular risk. Lancet (2007) 3.47
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int (2011) 3.32
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension (2003) 3.29
Update on myocarditis. J Am Coll Cardiol (2012) 3.12
The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension (2012) 3.07
Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 2.97
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension (2011) 2.68
"Stress" and coronary heart disease: psychosocial risk factors. Med J Aust (2003) 2.63
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm (2012) 2.60
Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation (2003) 2.59
Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol (2002) 2.54
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry (2008) 2.43
Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation (2002) 2.38
Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension (2003) 2.34
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med (2009) 2.28
Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation (2005) 2.25
Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ Res (2006) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med (2007) 2.20
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med (2009) 2.18
Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension (2012) 2.17
Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J (2010) 2.12
Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens (2007) 2.09
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension (2008) 2.09
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07
Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil (2011) 2.05
Targeting the sympathetic nervous system: critical issues in patient selection, efficacy, and safety of renal denervation. Hypertension (2013) 2.04